No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Mugdha N GokhaleJohn B BuseMichele Jonsson FunkJennifer LundVirginia PateRoss J SimpsonTil StürmerPublished in: Diabetes, obesity & metabolism (2017)
Although limited by the short treatment period, the present study suggests there is no increased short-term risk of MI, stroke or HF with DPP-4 inhibitors vs SUs/TZDs.